Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of “Moderate Buy” from Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $7.25.

MIST has been the subject of a number of analyst reports. Zacks Research downgraded Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, May 15th. Raymond James Financial began coverage on Milestone Pharmaceuticals in a report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price objective on the stock. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Wells Fargo & Company dropped their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th.

Insiders Place Their Bets

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total transaction of $82,490.00. Following the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.03% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in MIST. Orbimed Advisors LLC bought a new position in Milestone Pharmaceuticals during the third quarter worth $6,444,000. Marshall Wace LLP raised its holdings in shares of Milestone Pharmaceuticals by 289.8% during the fourth quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after purchasing an additional 1,231,793 shares during the period. Pathstone Holdings LLC bought a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $2,000,000. Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $1,333,000. Finally, Two Sigma Investments LP acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at about $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Trading Down 2.3%

Shares of MIST opened at $1.29 on Wednesday. The stock’s 50-day moving average is $1.46 and its two-hundred day moving average is $1.68. The stock has a market cap of $160.60 million, a PE ratio of -1.90 and a beta of 0.97. Milestone Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $3.06. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.11 million. Equities analysts forecast that Milestone Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.